New Research Highlights Potential And Pitfalls Of BRAF Inhibitors
This article was originally published in Pharmaceutical Approvals Monthly
Surprisingly positive data from two early-stage trials in metastatic melanoma with Plexxikon/Roche’s BRAF inhibitor, PLX-4032, and its quick move into Phase III, is garnering attention for the new class of cancer therapy. But there is one troubling sign of toxicity, and other research on the BRAF pathway is prompting debate over the pros and cons of specific versus broad activity.
You may also be interested in...
The newly relocated biotech is shifting its focus from science to business development as it moves its third compound into the clinic and begins looking for partners for its other programs.
As its melanoma drug advances in the clinic, Plexxikon obtains rights to co-promote it in the U.S.
To management's frustration, the biotech's deals with Novartis and Amgen haven't helped its market cap, one more sign that validating deals with Big Pharma don't move investors.